Littleton, CO (June 10th, 2011) – Novus Biologicals, a leading provider of antibodies and antibody related research products, announced today the release of a new product line for epigenetics research called Epi-ProTM antibodies. Over the past several months, Novus has collaborated with 21st Century Biochemicals, a leading manufacturer of custom antibodies and peptides, to generate the most well validated antibodies for modified histones and other epigenetic targets.
Several histone modifications have been shown in recent literature to affect the regulation of transcription and further epigenetic effects. While each modification has been associated with specific effects on the epigenetic code and subsequent phenotypes, histone modifications are part of a complicated system of checks and balances at the epigenetic level and there are many other remaining relationships to discover.
The laboratory teams at both Novus and 21st Century Biochemicals have performed extensive validation work in multiple assay types, including chromatin immunoprecipitation (ChIP), Western Blot, dot blots using modified peptide arrays, and immunocytochemistry (ICC). Therefore, you can be assured that all Epi-ProTM antibodies have been extensively characterized and validated, and are of the highest quality compared to other similarly commercially available products.
The initial list of currently available Epi-ProTM antibodies is included below, and over the next several months Novus will be releasing additional antibodies for this product line.
H3pT6 Antibody (NB21-1051)
H3pS10/pT11 Antibody (NB21-1092)
H3pT11 Antibody (NB21-1101)
H3K4me2 Antibody (NB21-1022)
H3K4me3 Antibody (NB21-1023)
H3K4ac Antibody (NB21-1024)
H3K4me1/pT6 (NB21-1037)
H3K4me3/pT6 Antibody (NB21-1039)
H3K9me1 Antibody (NB21-1071)
H3K9me2 Antibody (NB21-1072)
H3K9me3 Antibody (NB21-1073)
H3K18me2 Antibody (NB21-1142)
H3K18me3 Antibody (NB21-1143)
H3K36me1 Antibody (NB21-1251)
H3K36me2 Antibody (NB21-1252)
H4K20me2 Antibody (NB21-2089)
H4K20me1 Antibody (NB21-2088)
Additional modified histone targets that are currently in development include R2, R3, K27, K44, K79, K91 and several dual modifications. Novus also offers a Histone Modification Map poster for quick and easy reference of the important epigenetic modification sites. Sign up here to request complimentary posters, catalogs and more.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus’ products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.
About 21st Century Biochemicals (www.21stcenturybio.com)
21st Century Biochemicals provides solutions for biomedical researchers worldwide ranging from the manufacture of polyclonal and monoclonal antibodies to custom and bioactive peptides, arrays, libraries and peptidomimetics. Consisting of a core of PhD scientists with decades of experience, 21st Century Biochemicals provides peptide and antibody solutions with the most rigorous peptide QC in the industry: nanospray MS and HPLC analysis as well as CID MS/MS peptide sequence confirmation. 100% of the peptides and antibodies provided by 21st Century Biochemicals are manufactured in their facility outside of Boston, MA, providing unmatched product quality and consistency.
Contact:
Nehal Saleh, PhD
Novus Biologicals Europe
12 Cambridge Science Park
Cambridge, CB4 0FQ, UK
Tel: +44 (0)1223 426001
Fax: +44 (0)871 971 1635
Email: europe@novusbio.com
Novus Biologicals Worldwide
PO Box 802
Littleton, CO 80160 USA
Tel: 1-888-50-NOVUS
Fax: 303-730-1966
Email: nehal@novusbio.com
